Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Morning Review
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
    • Insider Transactions
  • inderesTV
  • Portfölj
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • Om oss
    • Följda bolag
    • Teamet
Regulatoriskt pressmeddelande

Bulletin from the Extraordinary General Meeting of Chordate Medical Holding AB (publ)

Chordate Medical Holding
Ladda ner börsmeddelandet

At the Extraordinary General Meeting of Chordate Medical Holding AB (publ), held on 17 July 2025, the following resolution was passed. All resolutions were adopted in accordance with the proposals previously made public in the notice to attend the meeting.

Approval of the Board of Directors’ resolution on a directed share issue
The General Meeting resolved, with the required majority in accordance with Chapter 16 of the Swedish Companies Act (commonly referred to as the “Leo rules”), to approve the Board of Directors’ resolution from 30 June 2025 on a directed issue of not more than 637,500 preference shares. The share issue entails an increase in the company’s share capital of up to SEK 2,550,000.

The new shares shall be subscribed for by Sifonen AB, Tommy Hedberg and related parties, and Caroline Brandberg and related parties. The subscription price was set at SEK 4.00 per share, which represents a premium compared to both the closing price on the day of the Board’s resolution and the volume-weighted average price (VWAP) over the 20 trading days preceding 30 June 2025.

The purpose of the share issue is to strengthen the company’s financial flexibility in line with its overall strategic plan.

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Bergs Securities AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments
Bulletin from the Extraordinary General Meeting of Chordate Medical Holding AB (publ)

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Ta kontakt
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.